Physician profile
Peter Coffman
NPI 1174559439
$48,991.29
in general payments reported to CMS, 2019-2025
20 companies · $4,175 in 2025
The $4,175 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,818 · 2020: $5,039 · 2021: $6,925 · 2022: $14K · 2023: $10K · 2024: $5,698 · 2025: $4,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $3,352 · Travel and Lodging: $1,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,300.00 |
| Food and Beverage | $3,351.88 |
| Travel and Lodging | $1,303.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $28,468.08 | 2021-2025 | Vraylar |
| Alkermes, INC. | $7,853.69 | 2020-2025 | Aristada, Lybalvi, Aristada Initio |
| Allergan, INC. | $6,329.47 | 2019-2020 | |
| Neuronetics, INC. | $1,186.98 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $938.70 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $710.54 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $644.62 | 2019-2025 | Spravato, Invega Sustenna, Invega |
| Lundbeck LLC | $519.48 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $482.28 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $423.15 | 2019-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $351.23 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $335.96 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $234.46 | 2021-2025 | Uzedy |
| Axsome Therapeutics, INC. | $169.09 | 2023-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $132.13 | 2020-2023 | Belsomra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $119.13 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $44.98 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.21 | 2025 | Rexulti |
| Corium, LLC | $16.11 | 2022 | |
| Owp Pharmaceuticals, INC. | $13.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Coffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.